EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Antithrombotic Management After Left Atrial Appendage Closure: Current Evidence and Future Perspectives

Jules Mesnier iD, Pedro Cepas-Guillén iD, Xavier Freixa, Eduardo Flores-Umanzor iD, Kim Hoang Trinh iD, Gilles O'Hara iD, Josep Rodés-Cabau iD

Circulation: Cardiovascular Interventions · 2023-05 · 16 (5)

DOI: 10.1161/circinterventions.122.012812 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Circulation: Cardiovascular Interventions, 2023-05. Verfasst von Jules Mesnier und 6 weiteren Autor:innen. Beteiligte Einrichtung: Quebec Heart and Lung Institute, Laval University, Québec City, Canada (J.M., K.H.T., G.O., J.R.-C.). Hauptthemen laut MEDLINE: Stroke, Atrial Appendage, Atrial Fibrillation, Thrombosis. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Left atrial appendage closure is an alternative to chronic oral anticoagulation to prevent embolic events related to nonvalvular atrial fibrillation. After device implantation, antithrombotic treatment is prescribed to prevent device-related thrombosis, a dreadful complication associated with an increased risk of ischemic events. However, the optimal antithrombotic treatment after left atrial appendage closure, effective on both device-related thrombus prevention and bleeding risk mitigation, remains to be determined. In more than 10 years experience with left atrial appendage closure, a wide range of antithrombotic treatments have been used, mostly in observational studies. In this review, we analyzed the body of evidence for each antithrombotic regimen after left atrial appendage closure to provide tools to guide the physician choice and describe future perspectives in the field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StrokeAtrial AppendageAtrial FibrillationThrombosisHumansAnticoagulantsFibrinolytic AgentsTreatment Outcome

Stichwörter der Autor:innen

anticoagulantsatrial appendageatrial fibrillationstroke, thrombosisthromboembolism

Substanzen

AnticoagulantsFibrinolytic Agents

Autor:innen und Institutionen

  • Quebec Heart and Lung Institute, Laval University, Québec City, Canada (J.M., K.H.T., G.O., J.R.-C.).
  • Cardiovascular Department, Cardiovascular Institute, Clínic Barcelona, Spain (P.C.-G., X.F., E.F.-U.).

ORCID-Profile: Jules Mesnier, Pedro Cepas-Guillén, Eduardo Flores-Umanzor, Kim Hoang Trinh, Gilles O'Hara, Josep Rodés-Cabau

Zitieren

APA

Mesnier, J., Cepas-Guillén, P., Freixa, X., Flores-Umanzor, E., Hoang Trinh, K., O'Hara, G., & Rodés-Cabau, J. (2023). Antithrombotic Management After Left Atrial Appendage Closure: Current Evidence and Future Perspectives. Circulation: Cardiovascular Interventions, 16(5). https://doi.org/10.1161/circinterventions.122.012812

Vancouver

Mesnier J, Cepas-Guillén P, Freixa X, Flores-Umanzor E, Hoang Trinh K, O'Hara G, et al. Antithrombotic Management After Left Atrial Appendage Closure: Current Evidence and Future Perspectives. Circulation: Cardiovascular Interventions. 2023;16(5). doi:10.1161/circinterventions.122.012812

BibTeX
@article{Mesnier2023,
  author = {Mesnier, Jules and Cepas-Guillén, Pedro and Freixa, Xavier and Flores-Umanzor, Eduardo and Hoang Trinh, Kim and O'Hara, Gilles and Rodés-Cabau, Josep},
  title = {Antithrombotic Management After Left Atrial Appendage Closure: Current Evidence and Future Perspectives},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2023},
  volume = {16},
  number = {5},
  doi = {10.1161/circinterventions.122.012812}
}
Kostenlos starten →